Study of Fecal Tumor M2-Pyruvate Kinase Level for Detection of Colorectal Cancer in Egyptian Adults
Abdel-Razek, F., Shawky, T., Shaheen, M., Mahgoub, A. (2646). Study of Fecal Tumor M2-Pyruvate Kinase Level for Detection of Colorectal Cancer in Egyptian Adults. EKB Journal Management System, 2025(1), -. doi: 10.58675/2682-339X.2854
Fathy Abdel-Razek; Taiseer Shawky; Mohamed Shaheen; Ahmed Mahgoub. "Study of Fecal Tumor M2-Pyruvate Kinase Level for Detection of Colorectal Cancer in Egyptian Adults". EKB Journal Management System, 2025, 1, 2646, -. doi: 10.58675/2682-339X.2854
Abdel-Razek, F., Shawky, T., Shaheen, M., Mahgoub, A. (2646). 'Study of Fecal Tumor M2-Pyruvate Kinase Level for Detection of Colorectal Cancer in Egyptian Adults', EKB Journal Management System, 2025(1), pp. -. doi: 10.58675/2682-339X.2854
Abdel-Razek, F., Shawky, T., Shaheen, M., Mahgoub, A. Study of Fecal Tumor M2-Pyruvate Kinase Level for Detection of Colorectal Cancer in Egyptian Adults. EKB Journal Management System, 2646; 2025(1): -. doi: 10.58675/2682-339X.2854

Study of Fecal Tumor M2-Pyruvate Kinase Level for Detection of Colorectal Cancer in Egyptian Adults

Al-Azhar International Medical Journal
Volume 2025, Issue 1, January 2025  XML
DOI: 10.58675/2682-339X.2854
View on SCiNiTO View on SCiNiTO
Authors
Fathy Abdel-Razek1; Taiseer Shawky1; Mohamed Shaheen2; Ahmed Mahgoub1
1Internal Medicine, Faculty of Medicine for Boys, Al-Azhar University, Cairo, Egypt
2Clinical Pathology, Faculty of Medicine for Boys, Al-Azhar University, Cairo, Egypt
Abstract
Background: In terms of both incidence and mortality rates, colorectal cancer (CRC) ranks third globally. Aim and objectives: Identifying colorectal cancer(CRC) in adult Egyptian patients by evaluating the fecal M2-PK™ (ScheBo-test) level as a potential new biomarker. Patients and methods: From August 2022 through January 2024, one hundred subjects participated in this case-control study. Fifty patients admitted to Al-Azhar University Hospitals' internal medicine and nuclear medicine departments with colorectal cancer were included in the cases group. As a control group, we used 50 individuals who seemed to be in good health(i.e., no colorectal cancer and normal colonoscopy results). Results: The examined patients group with CRC had significantly increased levels of fecal M2-PK (p˂0.001). In the control group, the median fecal M2-PK level was 0.91U/ml, with a range of 0.12U/ml to 15.4U/ml. Case group fecal M2-PK levels ranged from 0.45U/ml to 71U/ml, with a median of 37U/ml. In this study, we found no statistically significant difference in the levels of fecal M2-PK between the sexes(P>0.05). Variable phases of Duke's disease were associated with significantly variable fecal M2-PK levels(P˂0.05). Conclusion: Despite numerous advancements in treatment, colorectal cancer continues to cause a great deal of suffering and death. Cancer cells often overexpress tumor M2-PK, a dimeric pyruvate kinase isoenzyme. Feces could be used to identify and quantify fecal M2-PK. Levels of fecal M2-PK correlated positively with TNM and Duke's stages.
Statistics
Article View: 18